Clinical trial
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC…
NCT00001383 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001383 |
|---|---|
| Title | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 |
| Official title | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | PSC 833, paclitaxel |
| Enrollment | 52 |
| Start date | Mar 1, 1994 |
| Completion | Jan 1, 2001 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: